Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$119.22MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Krish S. Krishnan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 295
- Beta
- 0.50
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 43.04
Financials
Revenue
$119.22M+93775.6%Net Income
$54.77MEBITDA
$67.64MFree Cash Flow
$71.22MEPS (diluted)
$1.79Shares Outstanding (diluted)
30.66M+617.0%Operating Expenses
$54.37MCash & Debt
$845.63MReturn of Capital
$108.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $389.13M | $204.83M | $7.08 |
| 2024 | $290.51M | $89.16M | $3.12 |
| 2023 | $50.70M | $10.93M | $0.40 |
| 2022 | $0.00 | $-139.97M | $-5.49 |
| 2021 | $0.00 | $-69.57M | $-3.13 |
| 2020 | $0.00 | $-32.17M | $-1.71 |
| 2019 | $0.00 | $-19.09M | $-1.20 |
| 2018 | $1.03M | $-10.89M | $-0.97 |
| 2017 | $0.00 | $-7.92M | $-1.48 |
| 2016 | $0.00 | $-1.15M | $-0.27 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $10.40
- Implied price
- $363.94
- Return from $330.00
- 2.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $180.94 — -45.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 30 | 35 | 40 | 45 |
|---|---|---|---|---|---|
| -2.0% | -13.5% | -10.3% | -7.5% | -5.0% | -2.7% |
| 3.0% | -9.1% | -5.7% | -2.7% | -0.1% | 2.3% |
| 8.0% | -4.7% | -1.1% | 2.0% | 4.7% | 7.2% |
| 13.0% | -0.2% | 3.5% | 6.7% | 9.6% | 12.2% |
| 18.0% | 4.2% | 8.0% | 11.4% | 14.4% | 17.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (9)
- Newszacks.com·2d ago·Neutral
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
View source ↗ - Newsglobenewswire.com·3d ago·Negative
…. Shireen Guide at the 14th PeDRA Annual Conference, October 15-17, 2026 PITTSBURGH, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today a positive clinical update supporting initial proof of concept for KB113, an intratumoral immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance, in the treatment of bas…
View source ↗ - News (RSS)seekingalpha·8d ago·Negative
Krystal Biotech: Vyjuvek's Success Is Becoming Its Growth Problem (Downgrade)
View source ↗ - News (RSS)seekingalpha·8d ago·Neutral
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value
View source ↗ - Newsseekingalpha.com·8d ago·Positive
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Vyjuvek, approved for DEB, is on track for blockbuster status in my view with $119.2m Q2 revenue and expanding global reach. KRYS maintains a $1.1bn cash position, a 40% operating margin, and trades at ~12x forward P/E, supporting attractive valuation.
View source ↗ - News (RSS)zerohedge·42d ago·Negative
Trump Admin Weighs Child Care Subsidies For Stay-At-Home Parents Trump Admin Weighs Child Care Subsidies For Stay-At-Home Parents The Trump administration is drafting a rule that would allow some married couples with a stay-at-home parent to receive federal child care subsidies, an initiative reportedly championed by Vice President JD Vance, according to the New York Times. The proposal would use the existing Child Care and Development Fund (CCDF), which has traditionally helped lower-income par
View source ↗ - News (RSS)economictimes·42d ago·Positive
Dividend stocks: Kalyan Jewellers, IREDA among over 150 stocks turning ex-record date this week. Do you own any? More than 150 companies, including Kalyan Jewellers, IREDA, Zee Entertainment Enterprises, NSDL and others have scheduled record dates for dividends during the week of September 7 (Monday) to September 11 (Friday).To be eligible for these corporate actions, investors must hold the shares in their demat accounts as of the respective record dates. The list is tentative, as more companie
View source ↗ - Newszacks.com·45d ago·Positive
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
View source ↗ - Newszacks.com·46d ago·Neutral
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
View source ↗
Earnings
Mon, Nov 2(in 2 weeks)
Consensus estimate $1.85 per share
Typical surprise +17.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$1.79 vs $1.70beat
- Mon, May 4$1.83 vs $1.45beat
- Tue, Feb 17$1.70 vs $1.62beat
- Mon, Nov 3$2.66 vs $1.12beat
- Mon, Aug 4$1.29 vs $1.08beat
- Tue, May 6$1.20 vs $1.38miss
Estimates and results for KRYS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KRYS officers and directors.
- Bought
- —
- Sold
- $48.8m
0 trades
69 trades
- Krishnan Sumasold
- Krishnan Sumasold
- Krishnan Sumasold
- Krishnan Sumasold
- Krishnan Sumasold
- Krishnan Sumasold
- Krishnan Sumasold
- Krishnan Sumasold
31 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Jan 20, 2023 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.